Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel
Summary
Onexton ® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.The Rx team continues to invest in bringing important products to market that provide savings to patients and healthcare systems."Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network.Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.Related Links DUBLIN, Jan. 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton ® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%).